Market Surveillance of Centrally-authorised Products

Since the implementation of the «future systems» in 1995, close collaboration and mutual recognition between the Competent Authorities (CAs) of the EU and the European Economic Area (EEA) have become the norm for registration procedures. Innovative medicinal products are now introduced onto the market in the EU and EEA in a timely and efficient manner. To date, more than 140 medicinal products have been authorised through the centralised procedure